American Cancer Society Updates Prostate Cancer Screening Guidelines
The American Cancer Society recommends men undergo PSA testing for prostate cancer screening: typically from age 50 to 69 every two years, and earlier and more frequently for high-risk groups.

In its updated guidelines, the organization recommends using the prostate-specific antigen (PSA) blood test for early prostate cancer detection. The previous version of the guidelines did not include a universal call for regular screening.
Men at average risk should undergo PSA testing every two years between the ages of 50 and 69. Black men are advised to begin annual screenings at age 45. The same schedule applies to men of other races if a close relative was diagnosed with prostate cancer before age 65 or if the disease was detected in multiple close relatives. If cancer was diagnosed in only one relative at age 65 or later, screening should also begin at age 45 but should be conducted every two years.
For men aged 70 to 74, the benefits and potential harms of screening are less clear—whether to continue screenings should be discussed with a physician. The organization does not recommend screening for men over 75, or for those with poor health and an expected lifespan of less than 10 years, regardless of age.
The American Cancer Society does not consider digital rectal examination a standalone screening test. It may be prescribed if there is suspicion of disease, such as an elevated PSA level. A high test result alone does not indicate the presence of cancer and does not require an immediate biopsy: it is recommended to confirm the result with a repeat test, followed by a prostate MRI or biomarker test if necessary.
If a man is found to have low-risk cancer in terms of growth or spread, the physician should offer active surveillance. This includes regular monitoring, including PSA tests, biopsies, and potentially MRI scans; treatment begins if there are signs of increased risk.





